stockrow
Friday 6 November 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
- EPS
- −11.3%
- Free cash flow
- −39.1%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
18.21
0.85
+4.90%
Follow DYN
Alert me
Dyne Therapeutics, Inc. (DYN) Shares outstanding
Dyne Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $128.4M, up 36.4% from $94.1M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $165.5M. Over the past ten years it has ranged from $2.4M (fiscal 2019) to $128.4M (fiscal 2025) — the current reading is the highest in ten years. Dyne Therapeutics, Inc. ranks 66th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $128.4M | 36.43% |
| FY2024 | $94.1M | 57.74% |
| FY2023 | $59.7M | 14.83% |
| FY2022 | $52.0M | 2.12% |
| FY2021 | $50.9M | 253.54% |
| FY2020 | $14.4M | 489.28% |
| FY2019 | $2.4M | (94.62%) |
| FY2018 | $45.4M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $165.5M | 0.25% |
| Mar 2026 | $165.0M | 28.49% |
| Dec 2025 | $128.4M | (9.43%) |
| Sep 2025 | $141.8M | 24.53% |
| 23 more quarters | Free account |
Against its own ten years
Low $2.4M
High $128.4M
Ten-year median
$51.4M
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| DNLI Denali Therapeutics Inc. compare | $192.1M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $175.5M |
| DYN Dyne Therapeutics, Inc. | $165.5M |
| VKTX Viking Therapeutics, Inc. compare | $118.1M |
| VRDN Viridian Therapeutics, Inc. compare | $107.9M |
| ELVN Enliven Therapeutics, Inc. compare | $66.2M |
| CELC Celcuity, Inc. compare | $54.8M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $46.4M |
| TLX Telix Pharmaceuticals Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item